Netherlands Wet Age-Related Macular Degeneration (AMD) Market, By Drug Class (Monoclonal Antibodies, Benzoporphyrin Derivative, Others), Product (Biologics, Biosimilar), Age Group (60–80 Years, Above 80 Years, 40–59 Years), Disease Type (Wet AMD, Dry AMD), Stages (Early AMD, Intermediate AMD, Advanced AMD, No AMD), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Netherlands Wet Age-Related Macular Degeneration (AMD) Market Analysis and Size

The burden of wet age-related macular degeneration continues to rise at a high speed as the population increases and the demographics reflect a majority of older people. As per the National Eye Institute, AMD is a primary cause of visual loss in the elderly. Currently, only a few drugs, primarily anti-VEGFs, are approved for the treatment of age-related macular degeneration. Also, the eylea segment dominated the market in 2021, having a revenue share of over 50.0%.     

 Data Bridge Market Research analyses a growth rate in the wet age-related macular degeneration (AMD) market in the forecast period 2023-2030. The expected CAGR of wet age-related macular degeneration (AMD) market is tend to be around 6.8% in the mentioned forecast period. The market is valued at USD 107.5 million in 2022, and it would grow upto USD 181.9 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Netherlands Wet Age-Related Macular Degeneration (AMD) Market Scope and Segmentation

Market Definition

Wet macular degeneration is a kind of long-lasting eye disorder that causes blurred vision or a blind spot in the central vision. It is generally caused by blood vessels that leak fluid or blood into the macula. This disease includes mild symptoms such as mild blurriness in the central vision or difficulty seeing in low lighting. In late AMD (wet or dry type), numerous people experience straight lines start to look wavy or crooked. A blurry area near the center of your vision is also observed.  

Netherlands Wet Age-Related Macular Degeneration (AMD) Market Dynamics

Drivers

• Growing Adoption of Treatment Drugs

There are various treatment drugs that help treat wet macular degeneration, which in turn increases the market's growth. For instance, in 2011, the FDA authorized Eylea, an intravitreal injection of aflibercept. It stops VEGF from working in wet AMD. Patients suffering from diabetic macular edema, wet AMD, and macular edema are well-treated with it. Furthermore, patients who received Beovu witnessed four times greater intraocular inflammation than the ones who received Eylea. Such elements influence people to choose Eylea over Beovu. Thus, this factor increases the growth of the market.

• Increased Growth of Hospital Pharmacy

According to the Royal National Institute of Blind People (RNIB), about 26.5 million people, in 2021, were at high risk of acquring this condition. Majority of the patients are managed with drugs, such as Lucentis, Eylea, and Beovu, which are administered intravenously in hospitals, quite well under the supervision of specialists. Therefore, the increasing demand for wet AMD treatment is expected to increase the number of hospital visits, thus boosting the market in this region.

Opportunities

• Increasing Rate of Elderly Population

In Netherlands, population aged 65 years and more in increasing rapidly. Population aged 65 years and above for Netherlands was 20.3% in 2022. The Netherlands' population of 65 years and above grew from 10.5 % in 1973 to 20.3 % in 2022 growing at an average annual rate of 1.36%.This increasing elderly population demands more of this wet AMD treatments, increasing the market growth. Thus, this factor helps in increasing the market growth.

• Rising Healthcare Expenditure And Government Support

The rising prevalence of cancer, and the increasing awareness for the disease and the associated treatment is also improving. Various government initiatives tend to provide better and more convenient treatments combined with favourable reimbursement policies that are expected to increase the industry growth. Moreover, growing acceptance of advanced therapies is projected to drive the market.

Restraints/Challenges

• Side-Effects of Wet AMD Drugs

There are several wet AMD drugs with several side-effects that hinder market growth. Effects such as retinal vasculitis, intraocular inflammation, concomitant vascular occlusion, dizziness, nausea, irreparable vision loss in patients is expected to hinder the growth. This impedes the market growth.

• Availability of Alternatives for Wet AMD

The availability of substitute drugs for wet AMD is hampering the market growth. The launch and development of biosimilars and high adoption of off-label drugs such as Avastin could inhibit the market growth. There was a launch of Lucentis that lost its patent and is getting expired in many of the countries. Additionally, Eylea is expected to lose its patent by 2023. Thus, this factor will hamper the market growth.

This wet age-related macular degeneration (AMD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the wet age-related macular degeneration (AMD) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Netherlands Wet Age-Related Macular Degeneration (AMD) Market Scope

The wet age-related macular degeneration (AMD) market is segmented on the basis of drug class, product, age group, disease type, stages, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Monoclonal Antibodies
• Trastuzumab
• Pertuzumab
• Bevacizumab
• Benzoporphyrin Derivative
• Aminolevulinic Acid
• Liposome
• Neoplasm
• Verteporfin
• Others

Product

• Biologics
• Biosimilar

Age Group

• 60–80 Years
• Above 80 Years
• 40–59 Years

Disease Type

• Wet AMD
• Dry AMD

Stages

• Early AMD
• Intermediate AMD
• Advanced AMD
• No AMD

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Competitive Landscape and Netherlands Wet Age-Related Macular Degeneration (AMD) Market Share Analysis

The wet age-related macular degeneration (AMD) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Netherlands presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Wet Age-Related Macular Degeneration (AMD) market.

Key players operating in the wet age-related macular degeneration (AMD) market include:

• Loop Road Holdings LLC (U.S.)
• Old Saw Mill Holdings LLC (U.S.)
• OSMR LLC (U.S.)
• Regeneron Capital International B.V. (Netherlands)
• Regeneron International Limited (Ireland) 
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Bayer AG (Germany)